Summary: The effects of a combined isoprenalinephenylephrine inhalant in chronic obstructive lung disease were assessed in 23 patients. Significant changes occurred in blood gas tensions after inhalation, together with an overall improvement in ventilation/perfusion ratios. Cardiac output and physiological shunt were not significantly increased. Hence the addition of phenylephrine probably prevents the increase of hypoxaemia which may result from the disproportionate ventilation/ perfusion ratio produced by sympathomimetics or xanthines used alone. The combination aerosol has a satisfactory bronchodilator effect, and is additionally safe if used by a severely hypoxic patient unaware of the seriousness of his condition.
Introduction
A fall in arterial oxygen tension or saturation may be produced by intravenous aminophylline (Halmagyi and Cotes, 1959; Daly and Howard, 1965; Rees et al., 1967a Rees et al., , 1968 Tai and Read, 1967a) , subcutaneous adrenaline (Halmagyi and Cotes, 1959; Rees et al., 1967b Rees et al., , 1968 , isoprenaline inhalation (Chapman and Hughes, 1966; Field, 1967; Lockhart et al., 1967; Knudson and Constantine, 1967; Palmer and Diament, 1967, 1968; Tai and Read, 1967a; Waddell et al., 1967; McDonald et al., 1968; Chapman, 1969; Chapman and Dowd, 1969; Warrell et al., 1970) , orciprenaline inhalation Chapman, 1969) , salbutamol inhalation (Bass et al., 1969; Chapman, 1969;  Hume, 1970) , papaverine and papaverine plus isoprenaline inhalation (Chapman and Dowd, 1969) , and atropine subcutaneously (Field, 1967) . On theoretical grounds this fall could be prevented by adding a pulmonary vasoconstrictor or a cardiac slowing drug to a beta-adrenergic bronchodilator. The present study was undertaken to explore this possibility by using an aerosol consisting of isoprenaline and phenylephrine. (Hackney et al., 1958 
Mixed venous oxygen content (Civo2) was calculated by rearrangement of the relationship QT=Vo2/Cao2 -Ci'o2. "Physiological-shunt" was calculated from the formula QS/QT = (CCO2 -Cao2)/(CCO2 -Cvo2) X 100.
Results
Though previously demonstrated reversibility of expiratory airflow obstruction was the criterion for entry into the trial, on their test days only 13 of the 23 patients showed an increase in FEV1 of 20% or more. This day-to-day variability in response to bronchodilator drugs is well known to all experienced investigators and has been documented by Hume and Gandevia (1957) and Altounyan (1964) . The results have therefore been separated into two groups: "responders" showing FEVy increase greater than 20% and "non-responders" showing FEV1 increase less than 20%. All the variables have been statistically analysed by testing for the significance of mean differences by a t test (Mainland, 1963) .
Ventilation
Responders.-Figs. 1-4 show FEV1, VCo2, VD/VE, and VA before and after inhalation. There were significant increases in FEV1 (P <0 001), Vco2 (P <0 05), and VA (P <0 05) with a significant decrease in VD/VE (P <0 01) indicating an increase Non-responders.-There were no significant changes in any of these variables.
Blood gases
Responders.-Figs. 5 and 6 show Pao2 and PaCo2 before and after inhalation. The increase in Pao2 is significant (P<0.02) and the decrease in Paco2 is significant (P<0.02). This, too, indicates the efficacy of the increased ventilation. There were no significant changes in arterial oxygen saturation, which is not surprising as most patients had only minimal hypoxaemia. No significant changes were found in pH.
Non-responders.-There were no significant changes in any of the variables.
Cardiac Output and Physiological Shunt
Responders. The increased perfusion may be due to localized pulmonary vasodilatation (beta2-adrenergic effect on vessels) or to increased cardiac output (betai-adrenergic effect on myocardium). Palmer et al. (1969) suggested that the latter mechanism is responsible because of the action of practolol (a selective beta,-blocking agent affecting the myocardium only) in preventing isoprenaline-induced increase in hypoxaemia. The falls in Pao2 after inhalation of salbutamol, reported by Bass et al. (1969) , Chapman (1969) , and Hume (1970) , however, are difficult to explain on this basis, since salbutamol, as a result of its selective action on beta2-adrenergic receptors, is claimed to have a minimal effect on the myocardium (Brittain et al., 1968; Kennedy and Simpson, 1969; Palmer et al., 1969 ).
The present study shows that the combination of isoprenaline plus phenylephrine does not cause the increase in hypoxaemia which may occur when sympathomimetics or xanthines are used alone. Indeed, the reverse occurs, with increase in Pao2 and decrease in Paco2. This effect is explicable in terms of increased effectiveness of the improved ventilation as shown by the increases in CO2 output and alveolar ventilation in the responding group and highly significant decreases in physiological dead-space/tidal-volume ratio.
Though the indirect CO2 Fick method of calculating cardiac output may be unreliable in the resting state, the high metabolic rate of the subjects would appear to have justified its use, in accordance with the views of Warrell et al. (1970) . The absence of change in cardiac output and in physiological shunt in this study suggests that phenylephrine prevented the increase which would have been expected from the use of isoprenaline alone whether or not any bronchial response occurred. This accords with previous reports that phenylephrine alone reduces cardiac output and that it is a pulmonary vasoconstrictor (Horvath and Knapp, 1954; Aviado and Schmidt, 1957) . Hence probably both mechanisms may be involved in the prevention of deterioration in ventilationperfusion relationships which may be produced by isoprenaline.
The degree of fall in Pao2 produced by bronchodilators is generally small but in some patients may be as much as 15 mm. Hg. The (Chapman and Hughes, 1967; Palmer and Diament, 1967; Read, 1967a, 1967b; Read, 1968; Chapman and Dowd, 1969; Hughes, 1969 
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Many patients with calcium-containing renal stones pass excessive quantities of calcium in their urine (Flocks, 1939; Hodgkinson and Pyrah, 1958) . A few of these patients have hypercalcaemia and are then usually shown to have primary hyperparathyroidism. The remainder show few biochemical abnormalities other than hypercalciuria. Albright et al. (1953) and Henneman et al. (1958) recognized a group of such patients, usually men, in whom the hypercalciuria was associated with a tendency to hypophosphataemia; the serum calcium was normal, though in the upper part of the normal range. They called this syndrome idiopathic hypercalciuria and showed that urinary calcium could be reduced with calcium deprivation. Peacock et al. (1968) confirmed these observations and suggested that the intestinal absorption of calcium is increased in most patients.
The mechanisms which underlie the increased intestinal absorption of calcium in idiopathic hypercalciuria are unexplained. Peacock et al. (1968) suggested that in many cases this is the primary abnormality while others contend that the increased intestinal absorption of calcium is a secondary response to the increased losses of calcium in the urine (Jackson and Dancaster, 1959; Edwards and Hodgkinson, 1965 
